Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy joining 6 (IGHJ6) is one of the joining (J) gene segments in the immunoglobulin heavy-chain locus, which is located on chromosome 14 in humans[2][3][4]. IGHJ6 plays a crucial role in the adaptive immune system, enabling B cells to generate diverse antibodies through V(D)J recombination—a process that re-arranges variable (V), diversity (D), and joining (J) gene segments to form the variable region of immunoglobulin heavy chains[1][2]. This diversity is fundamental to the body's ability to recognize and respond to a broad array of antigens. Polymorphisms and variation in IGHJ6 and other IGH gene segments can impact individual immune responses and have been associated with differences in disease susceptibility and therapeutic antibody effectiveness[2]. IGHJ6 itself is not a therapeutic target but is critical for antibody repertoire formation in B cells. Neither drugs nor therapeutic mechanisms act directly on this segment, though its genetic variation is studied in immunogenetics and immune response research[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy joining 6 (IGHJ6).